China Advanced Care Gateway
CAR-T & Cellular Immunotherapy
Eligibility review for CAR-T and cellular immunotherapy programmes at accredited centres, including selected solid-tumour programmes where appropriately available.
What this pathway covers
- CAR-T eligibility review
- Cellular immunotherapy
- Haematological malignancies
- Selected solid-tumour programmes where appropriately available
- Innovative immune-based treatment pathways
Other pathways
CrossCare Global is a healthcare coordination platform. It is not a hospital and does not diagnose, treat or determine clinical eligibility. Treatment availability and eligibility depend on individual medical evaluation, hospital acceptance, regulatory requirements and current clinical protocols. Nothing here guarantees admission, treatment outcomes or visa approval.